Letrozole Biogaran

Letrozole, the active ingredient in Letrozole Biogaran, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine therapy of hormone‑receptor positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Letrozole is an aromatase inhibitor used in the treatment of breast cancer that depends on estrogen signaling. - Hormone receptor‑positive breast cancer (postmenopausal): reduces estrogen production to slow tumor growth. - Adjuvant therapy for early‑stage breast cancer (postmenopausal): helps prevent recurrence after surgery. - Metastatic breast cancer (postmenopausal): improves progression‑free survival.

Letrozole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint or muscle pain: aching in limbs or back. - Fatigue: persistent tiredness not relieved by rest. - Nausea: upset stomach, sometimes with vomiting. - Headache: mild to moderate intensity. - Dizziness: light‑headed sensation, especially when standing.

Serious or Rare Side Effects: - Severe bone loss or osteoporosis: increased fracture risk. - Liver function abnormalities: elevated enzymes indicating hepatic stress. - Cardiovascular events: hypertension, thromboembolic episodes. - Severe allergic reactions: rash, swelling, breathing difficulty. - Elevated cholesterol levels: may worsen lipid profile. - Bone pain with possible fractures: persistent skeletal discomfort.

Before initiating Letrozole therapy, several safety considerations are recommended. - Bone health monitoring: assess bone mineral density regularly. - Liver function assessment: perform baseline and periodic liver enzyme tests. - Cardiovascular risk evaluation: review history of hypertension or clotting disorders. - Avoid use in premenopausal women: drug is ineffective without postmenopausal estrogen status. - Review concomitant medications: check for interactions that may alter letrozole levels. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase letrozole concentrations. - Estrogen replacement therapy: counteracts letrozole’s estrogen‑lowering effect.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may alter INR, requiring closer coagulation monitoring. - Statins: potential additive effect on liver enzymes, monitor hepatic function. - Selective serotonin reuptake inhibitors (SSRIs): may influence hormone metabolism, observe for side‑effect changes.